Third Rock Ventures Launches Fulcrum Therapeutics with $55M Series A Investment

  • 7.22.2016

Third Rock Ventures, LLC announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes.

Fulcrum was established with $55 million in Series A financing to further develop a cross-disciplinary product engine to identify and modulate gene regulatory targets core to disease. Through its product engine, Fulcrum will develop a robust across therapeutic areas, spearheaded by two initial programs in genetic diseases.

The WilmerHale team on the deal was led by Partner Lia Der Marderosian, Senior Associate Stephanie Singer and Associate Byron Crowe.

Read the Fulcrum Therapeutics press release for more information.